Advertisement

PharmacoEconomics & Outcomes News

, Volume 840, Issue 1, pp 21–21 | Cite as

Pemetrexed + cisplatin in NSCLC not cost effective in Thailand

Clinical study
  • 6 Downloads

Reference

  1. Permsuwan U, et al. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Value in Health Regional Issues : 18 Oct 2019. Available from: URL: https://doi.org/10.1016/j.vhri.2019.04.005

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations